Engineering the Future of Precision Immunotherapy
Escalante Therapeutics is a biotechnology company advancing breakthrough immunotherapies through the integration of artificial intelligence, computational biology, and protein engineering. We are dedicated to developing next-generation T-cell receptor (TCR) therapeutics that redefine the boundaries of cancer and immune disease treatment.
Our vision is to bridge the gap between computational discovery and clinical excellence. By combining Physics-Aware AI with experimental validation, we are building a pipeline that accelerates the development of selective and potent TCR therapies for complex oncology and immunology challenges.
Our Scientific Pillars
Translational Research
We bridge the gap between computational biology and clinical reality. Our integrated workflows ensure that every AI-driven prediction is rigorously validated through experimental biology, accelerating the path to human trials.
TCR Engineering
We utilize proprietary AI to optimize T-cell receptor affinity and specificity. Our platform identifies rare, high-potency binding motifs that are often missed by traditional experimental methods, leading to next-generation candidates.
Precision Medicine
Our approach is fundamentally personalized. By leveraging deep learning to map complex protein interactions, we design TCRs that are highly selective for specific tumor antigens, minimizing off-target effects and maximizing therapeutic efficacy.